Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Reaches New 52-Week Low - Time to Sell?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) shares hit a new 52-week low on Wednesday . The company traded as low as $4.92 and last traded at $4.92, with a volume of 1992218 shares changing hands. The stock had previously closed at $5.03.

Wall Street Analyst Weigh In

Separately, Bank of America upgraded shares of Bayer Aktiengesellschaft from an "underperform" rating to a "neutral" rating in a research note on Friday, September 6th. One investment analyst has rated the stock with a sell rating and five have assigned a hold rating to the stock. Based on data from MarketBeat, Bayer Aktiengesellschaft presently has a consensus rating of "Hold".

Bayer Aktiengesellschaft Price Performance

The stock has a market capitalization of $19.33 billion, a PE ratio of -18.92 and a beta of 1.03. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.81 and a current ratio of 1.32. The stock's 50-day moving average is $6.04 and its 200 day moving average is $7.00.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.17 by ($0.10). Bayer Aktiengesellschaft had a positive return on equity of 16.90% and a negative net margin of 2.02%. The firm had revenue of $10.96 billion for the quarter. As a group, equities analysts expect that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.